Paula Cannon
From Wikipedia, the free encyclopedia
American biologist
This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
(Learn how and when to remove this message)This biography of a living person needs additional citations for verification . Please help by adding reliable sources. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libelous.
Find sources: "Paula Cannon" – news · newspapers · books · scholar · JSTOR (September 2020) (Learn how and when to remove this message)
Find sources: "Paula Cannon" – news · newspapers · books · scholar · JSTOR (September 2020) (Learn how and when to remove this message)
This article is an orphan, as no other articles introduce links to this page from related articles ; try the Find link tool for suggestions. (November 2021)
Paula Cannon | |
|---|---|
| Nationality | British |
| Alma mater | University of Liverpool, UK |
| Scientific career | |
| Fields | Genetics |
| Institutions | University of Southern California (USC) |
Paula Cannon is a British geneticist and virologist, Distinguished Professor of Molecular Microbiology & Immunology at the University of Southern California.[1] She is a specialist in gene therapy, hematopoietic stem cells, and human immunodeficiency virus (HIV) with particular interest in gene editing and humanized mice.
Personal life and education
[edit ]She received her PhD from the University of Liverpool, and postdoctoral training at both Oxford and Harvard [1]
Academic career
[edit ]Cannon's recent work is aimed at disrupting the CCR viral co-receptor, CCR5, using zinc finger nucleases(ZFNs). She also studies SARS-CoV-2 and highly pathogenic hemorrhagic fever viruses, including Ebola and Lassa fever viruses.[1]
Selected publications
[edit ]Her most cited peer-reviewed publications are:
- Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids research . 1995 Feb 25;23(4):628-33. [2] open access Cited 932 times, according to Google Scholar,[2]
- Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nature Biotechnology . 2010 Aug;28(8):839-47. Cited 762 times, according to Google Scholar [2]
- Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine . 2016 Aug;22(8):839-50. [3] Cited 375 times, according to Google Scholar [2]
- Gardner MR, Kattenhorn LM, Kondur HR, Von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature . 2015 Mar;519(7541):87-91. [4] Cited 275 times, according to Google Scholar [2]
- Wang J, Exline CM, DeClercq JJ, Llewellyn GN, Hayward SB, Li PW, Shivak DA, Surosky RT, Gregory PD, Holmes MC, Cannon PM. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nature biotechnology. 2015 Dec;33(12):1256-63. Cited 242 times, according to Google Scholar [2]
References
[edit ]External links
[edit ]- Paula Cannon publications indexed by Google Scholar